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Background: 5-Fluorouracil (5-FU) is an antimetabolite, which is frequently used as chemotherapeutic agent for
combined chemoradiotherapy. The purpose of this study was to present the clinical course of three patients who
developed severe cardiac toxicity by 5-FU and to give a review of the literature on the cardiotoxic potential of 5-FU.
Results: Cardiotoxicity is a rare, but relevant side effect of fluoropyrimidines. It comprehends a wide spectrum of
side effects, from electrocardiogram changes (69% of cardiac events) to myocardial infarction (22%) and cardiogenic
shock (1%).
In this case series three patients with cardiotoxic events during chemoradiotherapy including 5-FU, the reaction's
characteristics and their influence on further therapy are described. Two of the patients could not be treated with
5-FU any more because they had developed a myocardial ischemia, which was most likely caused by fluorouracil.
Another patient, who complained about typical angina pectoris during 5-FU-infusion and had a new left anterior
hemiblock, was reexposed with prophylactic administration of nitrendipine.
Conclusion: Cardiotoxicity caused by 5-FU is an underestimated problem in radiooncology. Especially patients
without history of cardiac disease are often treated as out-patients and therefore without cardiac monitoring.
Consequently asymptomatic and symptomatic cardiac events may be overlooked. The benefit of prophylactic
agents remains unclear, so close cardiac monitoring is the most established method to prevent manifest cardiotoxic
events.Background
5-Fluorouracil (5-FU) is an antimetabolite, which, in
radiooncology, is frequently used as chemotherapeutic
agent during simultaneous chemoradiotherapy. It is
mainly applied in neoadjuvant and definitive chemora-
diotherapy of gastrointestinal malignancies and carcin-
oma of head and neck. Fluoropyrimidine therapy may
cause frequent side effects like myelosuppression, muco-
sitis, nausea, emesis and hand-foot-syndrome, but is also
associated with toxic cardiac reactions [1,2]. These com-
prehend a wide spectrum from asymptomatic electrocar-
diogram (ECG)-changes and subacute, transient arrhy
thmias through to potentially life threatening events like
myocardial ischemia and cardiogenic shock [3,4]. If one
considers the frequency of 5-FU-induced cardiac side
effects as documented in the literature, cardiac toxicity
represents a problem which is underestimated in radio* Correspondence: felix.steger@ukr.de
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reproduction in any medium, provided the oroncology. Those patients who do not have cardiovascular
risk factors are often treated as outpatients and without
cardiac monitoring. Consequently asymptomatic as well
as symptomatic cardiac events remain undiscovered. This
leads to a discrepancy between reported and real toxicity,
concerning both asymptomatic ECG-changes [5] and sub-
acute, but symptomatic incidents which could not be
observed or do not come up in the conversation between
patient and physician.
A meta-analysis by Saif et al. shows the distribution and
frequency of cardiac reactions. Hence pectoral angina,
myocardial infarction and arrhythmias belong to the most
common cardiac events caused by fluoropyrimidines. The
patients who are taken into account in this analysis were
treated for gastrointestinal malignancies, cancer of head
and neck as well as mamma carcinoma without concur-
rent radiotherapy. 14% of them had a history of cardiac
disease, cardiac risk factors were known with 37% of the
patients. Also in the normal population, the prevalence of
cardiovascular disease is high. According to data of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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people suffer from cardiovascular disease.
The following data clearly demonstrate the relevance
of the cardiotoxic reactions during 5-FU therapy: 8% of
the persons with cardiac events died after primary ex-
position – after being reexposed, the rate of lethal com-
plications reached 13% [6].
Despite cardiotoxicity of fluorouracil is a rare event, it
can be regularly seen. Three cases of cardiotoxicity dur-
ing chemoradiotherapy containing 5-FU-infusion are
described below.
Case presentation
Case 1
A 73-year-old man was treated for an esophageal carcin-
oma. The diagnosis of carcinoma was made when the
patient developed a symptomatic, but subacute non-ST-
segment elevation myocardial infarction (NSTEMI).
Basic diagnostic showed an advanced anaemia with
hemoglobin concentration of 5.9 g/dl. Further investiga-
tion could explain this by a distal adenocarcinoma of the
esophagus (cT3 cN1 cM0 G2). Coronary angiography
provided a medium grade stenosis both of the anterior
descendant branch of left coronary artery and right cor-
onary artery without any need for intervention. Echocar-
diographically an ejection fraction of 60% and a low
grade diastolic dysfunction could be demonstrated.
Given the moderate findings of diagnostics, the myocar-
dial infarction was seen in connection with advanced an-
aemia. Hence, in interdisciplinary consensus, primary
chemoradiotherapy with continuous infusion of 5-FU
(1000 mg/qm per day, day 1 – 4) and cisplatinum
(60 mg/qm, day 1) including cardiac monitoring was
indicated. The therapeutic concept included irradiation
of distal esophagus including locoregional lymphatic re-
gion with single doses of 1.8 Gy to a total dose of
66.6 Gy. Before the beginning of the therapy the
patient's medication was adapted to the new diagnosis of
coronary artery disease and myocardial infarction.
During the first cycle of concurrent chemotherapy, after
approximately 93 hours of 5-FU-infusion (total applicated
dose about 6800 mg), the patient developed an angina
pectoris, so that application had to be stopped. SymptomsFigure 1 ECG after beginning of pectoral angina. New significant ST-secompletely disappeared within few minutes for four hours,
then the patient again complained about retrosternal chest
pain and ECG showed new tachycardia. The patient was
transferred to intensive care unit for monitoring, and
further diagnostics revealed new significant ST-segment
elevations (Figure 1), negative heart enzymes and intermit-
tent atrial fibrillation. Consequently, the patient was trea-
ted with digitoxin, the dose of bisoprolol was increased
and therapeutic anticoagulation was carried out. In the
course of the day, ST-segment changes as well as atrial fib-
rillation disappeared and the patient became asymptom-
atic. Few ventricular extrasystoles could be detected in
long-term ECG.
Taking all into conclusion, findings were interpreted as
5-FU-induced transient myocardial ischemia with syn-
chronal atrial fibrillation. Because of the increased risk
of recurrent cardiotoxicity, no further chemotherapy was
applied. Radiotherapy could be completed without fur-
ther complications.
Case 2
A 49-year-old patient had a rectal carcinoma (uT3
uN1 cM0, adenocarcinoma G2, ranging from the
anocutaneous line to 8 cm above) and was treated
with neoadjuvant chemoradiotherapy including continu-
ous 5-FU-infusion (1000 mg/qm per day, day 1 – 5) in
first and fifth weeks of therapy. Radiotherapy was carried
out with single doses of 1.8 Gy five times a week to a total
dose of 50.4 Gy. At the time of diagnosis, the male patient
was in good general constitution with no history of car-
diac disease. He declared a nicotine abuse of 15 cigarettes
per day, furthermore his father had died of myocardial in-
farction at the age of 63 years. Pretherapeutic ECG did
not show any signs of myocardial ischemia, infarction or
arrythmia.
During the application of the first cycle of 5-FU the
patient developed a typical angina pectoris approxi-
mately 54 hours after the beginning of infusion. Symp-
toms improved after treatment with nitroglycerin and
cessation of 5-FU-application (total applicated dose
about 4400 mg). The ECG performed immediately after-
wards revealed a new left anterior hemiblock, above that
the following day exercise electrocardiography showedgment elevation.
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toms. However, there were no signs of ischemia in myo-
cardial scintigraphy even during exercise, furthermore
no hypokinesia could be found echocardiographically.
Taking these diagnostic results into consideration
and in the absence of clinical symptoms, it was decided
to continue simultaneous 5-FU-therapy with prophy-
lactic administration of a calcium channel blocker. A
second cycle of chemotherapy was given with concur-
rent taking of nitrendipine 10 mg two times a day. In
these conditions neoadjuvant chemoradiotherapy could
be continued without further complications.
Case 3
A 59-year-old patient who had an adenocarcinoma of
the rectum (uT2 cN1 cM0 G2, 6–10 cm from the anocu-
taneous line), was treated with neoadjuvant chemora-
diotherapy, too. The male patient was in good general
constitution, moreover no pre-existing cardiac disease
or risk factors apart from obesity could be deter-
mined. Consequently, neoadjuvant chemoradiotherapy
with continuous 5-FU-infusion (1000 mg/qm per day,
day 1 – 5) was indicated. Radiotherapy was applied by
analogy to the concept of the second patient.
During the first cycle the patient developed pectoral
angina approximately 65 hours after the beginning of in-
fusion. Consequently, application of 5-FU was stopped.
ECG did not show any signs of ischemia, but symptoms
were responsive to nitroglycerin. Six hours after onset of
the symptoms a significant elevation of troponin I could
be observed, so that a NSTEMI was diagnosed. Coron-
ary angiography, which was consequently performed, did
not reveal any relevant stenosis. Thus, the described car-
diac event was interpreted as 5-FU-induced myocardial
ischemia.
As a consequence, it was decided not to reexpose the
patient with fluorouracil and the further neoadjuvant
therapy was carried out as radiotherapy alone.
Conclusions
In addition to the cardiac side effects mentioned above
there are further cardiotoxic reactions described in the
literature. The review by Saif et al. specifies the following
events and their distribution in relation to the total
number of cardiac side effects [6]: ST-T changes (69% of
cardiac events), Angina pectoris (45%), Arrhythmias
(23%), Myocardial infarction (22%), Abnormal car-
diac enzymes (12%), Pulmonary embolism (5%), Cardiac
arrest/pericarditis (1.4%).
As regards to general frequency of cardiotoxic side
effects there are inconsistent data in the literature, but
for the most part the risk is considered to be a single-
digit percentage. It ranges from 1.6% of 5-FU-exposed
patients [4] through 7.6% [7] in collectives that are notpreselected involving patients having a history of cardiac
disease, to 8% [8] within a group of heart-healthy patients.
Due to different inclusion criteria, this data is only com-
parable to a limited extent. Above that some studies
showed an influence of 5-FU-application-protocol to fre-
quency of cardiotoxic side effects. If fluorouracil is applied
as continuous infusion, the risk of cardiotoxicity seems to
be higher than with bolus application or short infusion
[9,10].
Although some influencing factors are well known, the
mechanism which is responsible for the effects men-
tioned above remains poorly defined. The following
causes are mainly discussed in the literature: direct myo-
cardial damage, vasospasm, increased oxygen demand,
rheological effects, autoimmune reaction, cytotoxic
effects, endothelial changes and impurities [6,11,12]. It
remains unclear which of the effects mentioned above is
responsible for cardiotoxicity of fluoropyrimidines. The
results to date do not lead to a distinct conclusion. Inter-
estingly a connection between circulating plasma levels
of fluorouracil and cardiac side effects does not seem to
exist [13]. Furthermore, patients with an insufficiency of
dihydropyrimidindehydrogenase (DPD), the key enzyme
of fluoropyrimidine metabolism, do not show elevated
rates of cardiotoxic reactions [14].
If there is a cardiotoxic event during primary applica-
tion of 5-FU, the question arises if there are viable
prophylactic options. Due to the theory of vasospasm-
induced myocardial ischemia or angina pectoris, calcium
channel blockers and nitrates are primarily used, similar
to the treatment of variant angina. In the second
reported case nitrendipine was applied successfully to
enable a rechallenge. We opted for this treatment due to
the fact that the patient had no history of cardiac disease
and had not developed an apparent myocardial infarc-
tion during the first cycle of concurrent chemotherapy.
Under such conditions, therapy could be continued
without further complications. In case of the other
patients the chemotherapy was discontinued because
the rechallenge to fluorouracil is associated with an
increased risk for serious complications. The first patient
had shown a new ST-segment elevation and previously
had suffered a myocardial infarction, the third patient
developed a NSTEMI which, in all likelihood, was 5-FU-
induced, considering that coronary angiography did not
show any relevant stenosis.
As regards the prophylactic use of calcium channel
blockers and nitrates, there are inconsistent data in pre-
vious studies. Cianci et al. treated two patients after first
cardiotoxic event with transdermal nitrates, above that
the dose of fluorouracil was reduced by 10-20%. During
rechallenge no further cardiotoxic event appeared [15].
There are further smaller publications which describe
the effectiveness of administration of prophylactic
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confirm the effect of calcium channel blockers or
nitrates in reducing the risk of cardiotoxicity. In a col-
lective of seven patients cardiotoxicity could not suc-
cessfully be prevented [16]. Eskilsson and Albertsson
compared within a total number of 97 patients a group
without prophylaxis with patients who received verap-
amil (120 mg three times a day), and their analysis did
not demonstrate a significant difference between these
groups with 12% vs. 13% recurrent cardiotoxicity [17].
However, at the moment there are no prospective rando-
mised studies that examine this issue.
Despite from that, administration of prophylactic
agents is widespread, all the more so as there are only
few alternatives for 5-FU in simultaneous chemora-
diotherapy. According to present data, also Capecitabine,
the oral prodrug of fluorouracil, has a comparable risk
of cardiotoxicity [18,19]. What is more, there are no che-
motherapeutic options with good evidence for effective-
ness and favourable risk profile, at least as far as
gastrointestinal malignancies are concerned.
Moreover, few data are available on predictive markers
for cardiac side effects of fluoropyrimidines. Elevated
plasma level of brain natriuretic peptide (BNP) is signifi-
cantly correlated with increased risk of cardiotoxicity
during 5-FU-infusion [20], but data still need to be
validated.
The most reliable method for early detection of car-
diac events during chemotherapy with 5-FU continues
to be close cardiac ECG-monitoring. Hereby myocardial
ischemia or arrhythmias can be detected before becom-
ing clinically manifest. However, to achieve that, close
monitoring of both patient and ECG is necessary.
In summary, cardiotoxicity of 5-FU is an underesti-
mated problem in radiooncology. There are no reliable
chemotherapeutic alternatives especially for therapy of
gastrointestinal malignancies. Moreover, the role of pre-
dictive markers still needs to be defined exactly. Prophy-
lactic application of calcium channel blockers or nitrates
is an option to enable rechallenge with 5-FU after cardi-
otoxic reaction during primary therapy, but more evi-
dence for effectiveness of these drugs in preventing
cardiotoxic reactions is needed. In conclusion, close car-
diac monitoring with, if necessary, cessation of 5-FU-
infusion continues to be the most established method.
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